Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Charlottesville, Virginia, founded in 2001. The company specializes in developing small-molecule therapeutics aimed at treating serious and life-threatening medical conditions by enhancing oxygen delivery to hypoxic tissues. Its lead product candidate, transcrocetinate sodium, is currently undergoing Phase III trials for glioblastoma multiforme and Phase II trials for metastatic brain cancer and acute stroke. Additionally, Diffusion is developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I trials for age-related macular degeneration and is in pre-clinical development for oncology, primarily targeting glioblastoma multiforme. The company has also established a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate transcrocetinate sodium in patients suffering from acute respiratory distress syndrome related to COVID-19 infection.
The company was formerly known as Stratus Media Group, Inc. Stratus Media Group, Inc. (Stratus) is a development-stage company. The Company owns or is targeting the acquisition of live entertainment companies in areas, such as action sports, auto shows, college sports, concerts & music festivals, food entertainment, diversified media marketing, motor sports, running events, trade shows and expos, and talent management. The Company is focusing on operating its portfolio of live entertainment events, activating existing properties, operating Stratus Rewards, and acquiring and aggregating a platform of live entertainment events. In June 2011, the Company acquired ProElite, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.